Table III.

Effects of treatment with isoflavones on the cardiac and pulmonary circulation of patients with CMS (n=28).

Time-point	MPA (mm)	RVEAD (mm)	RVETD (mm)	RVAW (mm)	RVOT (mm)
Prior to treatment	23.38±2.70	23.39±3.12	30.71±3.75	5.89±1.22	33.89±3.59
Following treatment	22.00±2.31	21.66±2.49	27.71±3.38	5.39±0.79	31.70±3.37
P-value	0.011	<0.001	<0.001	0.010	0.002

Values represent the mean ± standard deviation. P-value, comparison between values prior to and following treatment with isoflavones. CMS, chronic mountain sickness; MPA, main pulmonary artery diameter; RVEAD, right ventricular end-diastolic anteroposterior diameter; RVETD, right ventricular end-diastolic trans diameter; RVAW, right ventricular anterior wall; RVOT, right ventricular outflow tract.